Oriana Zerbini of CROM Srl chats to EPCabout the role of CROs in the evolving pharmaceutical industry
Let’s start with CROM group’s core competencies – what are the main success stories so far?
The experience we’ve acquired over the years enables us to operate in various therapeutic areas. We supply our clients with solutions tailored to a selection of the best researchers, centres and countries in which to carry out research in keeping with the chosen timescale, and based on the regulatory regimes of the individual countries involved. The opening of new branches in the Ukraine and Poland in 2000 has certainly been a crucial turning point for CROM. We are not only expanding into new countries, but also in terms of projects; in 2006 CROM managed 76 active studies carried out in 869 centres and involving 16,367 patients.
What are your main operational strengths?
We really know how to focus on particular goals and share these aims with our clients, notably: organisation; professionalism; knowledge of the sector and of healthcare and regulatory conditions in individual countries; flexibility and problem-solving; respect of human resources as a true ‘added value’; application of metrics as a key tool for managing an entire process; and finally, the application of an appropriate methodology and principles of quality control as ways to manage the entire clinical research process. |
